Vertex Pharmaceuticals Incorporated

180 articles about Vertex Pharmaceuticals Incorporated

• Vertex Announces European Commission Approval for KALYDECO® (ivacaftor) for Children and Adolescents With Cystic Fibrosis Between the Ages of 6 Months and 18 Years With the R117H Mutation in the CFTR Gene

  6/10/2020

  KALYDECO® (ivacaftor) is the first and only approved medicine in Europe to treat the underlying cause of cystic fibrosis in patients with the R117H mutation, the most common residual function mutation, in children as young as 6 months of age

• CRISPR Therapeutics and Vertex Pharmaceuticals Announce FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX001™ for the Treatment of Severe Hemoglobinopathies

  5/11/2020

  CTX001 has received Orphan Drug Designation from the U.S. Food and Drug Administration for transfusion-dependent beta thalassemia and from the European Medicines Agency for sickle cell disease and transfusion-dependent beta thalassemia

• Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) for Children and Adolescents With Cystic Fibrosis Between the Ages 6 Months and 18 Years With the R117H Mutation in the CFTR Gene

  5/1/2020

  If approved, KALYDECO® (ivacaftor) will be the first and only medicine in Europe to treat the underlying cause of cystic fibrosis in patients with the R117H mutation, the most common residual function mutation, as young as 6 months of age

• Vertex Announces Virtual 2020 Annual Meeting and Internet Access to Proxy Materials

  4/28/2020

  Vertex Pharmaceuticals Incorporated announced that, due to public health and travel safety concerns related to the ongoing COVID-19 pandemic, its 2020 Annual Meeting of Shareholders will be held as a virtual meeting.

• Vertex Announces Innovative Reimbursement Agreement in Switzerland for ORKAMBI® (lumacaftor/ivacaftor) and SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Cystic Fibrosis Patients

  4/21/2020

  Agreement also enables the possibility of rapid patient access to future triple combination regimen (elexacaftor/tezacaftor/ivacaftor and ivacaftor) once approved in Switzerland

• The Vertex Foundation Commits $5 Million to Support Global COVID-19 Pandemic Response

  4/7/2020

  Vertex Pharmaceuticals Incorporated announced that the Vertex Foundation, a nonprofit charitable foundation, commits to make donations totaling $5 million in 2020 to support global COVID-19 relief efforts, including doubling its match for employees’ charitable donations to eligible organizations responding to the COVID-19 pandemic.

• Vertex Confirms Supply Chain Continuity and Business Outlook for Its Cystic Fibrosis Medicines and Provides Initial Update on Development Programs

  3/27/2020

  Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today confirmed its 2020 business outlook and the continuity of the company’s supply chain for its approved cystic fibrosis (CF) medicines and provided an update on its development programs given the ongoing COVID-19 pandemic. “Despite the widespread impact of the COVID-19 pandemic, the outlook for our business remains unchanged and we continue to be highly confident in ou

• The Vertex Foundation Donates $500,000 to Partners HealthCare to Support COVID-19 Outbreak Response

  3/13/2020

  Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the Vertex Foundation, a nonprofit charitable foundation, is making a $500,000 gift to Partners HealthCare, a Boston-based nonprofit hospital and physician network, to support the needs of patients and health care providers and bolster preparedness and response to the ongoing novel coronavirus (COVID-19) outbreak through enhanced testing capacity.

• Vertex to Present at the Cowen Health Care Conference on March 3, 2020

  2/25/2020

  Vertex Pharmaceuticals Incorporated announced that management will present at the Cowen Health Care Conference on Tuesday, March 3, 2020 at 10:00 a.m. ET..

• Vertex Announces Availability of Cystic Fibrosis Medicine KALYDECO® (ivacaftor) in New Zealand

  2/25/2020

  Vertex Pharmaceuticals Incorporated announced that KALYDECO® will be available to eligible patients with cystic fibrosis in New Zealand from March 1.

• Vertex to Announce Full-Year and Fourth-Quarter 2019 Financial Results on January 30

  1/21/2020

  Vertex Pharmaceuticals Incorporated will report its full-year and fourth-quarter 2019 financial results on Thursday, January 30, 2020 after the financial markets close.

• Vertex to Present at the J.P. Morgan Healthcare Conference on January 13

  1/8/2020

  The audio portion of management’s remarks can be accessed live through Vertex’s website, www.vrtx.com, in the “Investors” section under the “News and Events” page.

• Vertex and Republic of Ireland Expand Long-Term Cystic Fibrosis Medicines Reimbursement Agreement to Include Triple Combination Therapy for All Eligible Patients Ages 12 and Over Once Licensed

  12/13/2019

  Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today confirmed that, following recent collaborative discussions, it has negotiated an agreement with the Health Service Executive (HSE) in the Republic of Ireland to expand the existing long-term cystic fibrosis (CF) reimbursement agreement to include the triple combination regimen (elexacaftor, tezacaftor and ivacaftor), which is under review and pending approval by the European Medicines Agency,

• French Authorities Approve National Reimbursement of ORKAMBI (lumacaftor/ivacaftor) for Eligible People Ages Two and Older With Cystic Fibrosis

  11/20/2019

  Vertex Pharmaceuticals Incorporated announced that the French Authorities have approved national reimbursement of ORKAMBI® for people ages two and older with cystic fibrosis who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator gene.

• CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001® for Severe Hemoglobinopathies

  11/19/2019

  CRISPR Therapeutics (NASDAQ: CRSP) and Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced positive, interim data from the first two patients with severe hemoglobinopathies treated with the investigational CRISPR/Cas9 gene-editing therapy CTX001 in ongoing Phase 1/2 clinical trials.

• Vertex Confirms Wales Offer Accepted for Access to All Licensed Cystic Fibrosis Medicines

  11/13/2019

  Eligible patients in Wales will soon have access to ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor), expanded access to KALYDECO® (ivacaftor) under same terms as NHS England agreement

• Vertex Announces Agreement with NHS England for Access to All Licensed Cystic Fibrosis Medicines

  10/24/2019

  Eligible patients in England will have access to ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor), expanded access to KALYDECO® (ivacaftor)

• ADDING MULTIMEDIA FDA Approves TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older Who Have at Least One F508del Mutation

  10/23/2019

  For the first time, approximately 6,000 patients with one minimal function mutation and one F508del mutation have a medicine to treat the underlying cause of their disease

• Spanish Government Approves National Reimbursement of ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor) in Combination With KALYDECO® (ivacaftor)

  10/21/2019

  Vertex Pharmaceuticals Incorporated announced that the Spanish Government has approved terms for the national reimbursement of ORKAMBI® and SYMKEVI® in combination with KALYDECO® for eligible patients in Spain living with cystic fibrosis

• Vertex to Announce Third-Quarter 2019 Financial Results on October 30

  10/21/2019

  To access the call, please dial (866) 501-1537 (U.S.) or +1 (720) 545-0001 (International).